Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma and mantle cell lymphoma. Roche’s heritage in non-hodgkin lymphoma treatment Rituximab ...

"We're helping people with autoimmune diseases and organ transplants to live ... lymphoma The often more aggressive diffuse large B-cell lymphoma For decades, treatments for non-Hodgkin's lymphoma ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a study published in the Journal of Clinical Investigation.

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

F. Hoffmann-La Roche Ltd (Roche) has a rich history of antibody therapies to treat cancers (malignancies) that affect B cells (a type of white blood cell), including non-Hodgkin lymphoma and ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).